Bicara Therapeutics INC 8-K filings

Bicara Therapeutics reports Q2 2026 progress, including strong enrollment in its pivotal FORTIFI-HN01 study and a planned CEO transition to Ryan Cohlhepp in January 2027.

Bicara Therapeutics announces the appointment of Jeremy Bender, Ph.D., and Christy Oliger to its Board of Directors, enhancing its strategic and commercial expertise.

Bicara Therapeutics reported that its lead drug candidate doubled the three-year survival rate for head and neck cancer patients compared to current standard treatments.

Bicara Therapeutics reported Q1 2026 financial results, highlighted progress in its pivotal FORTIFI-HN01 trial for ficerafusp alfa, and announced key executive appointments.

Bicara Therapeutics initiated Phase 3 of its pivotal FORTIFI-HN01 trial, strengthened liquidity with a $161.8M offering, and guided to an interim readout in mid-2027 while reporting higher FY25 R&D spend and net loss.

Bicara Therapeutics Inc. successfully closed a public offering of common stock and pre-funded warrants, raising approximately $161.8 million in net proceeds to advance its lead oncology candidate, ficerafusp alfa.

Bicara Therapeutics announced positive Phase 1b data for ficerafusp alfa in HPV-negative recurrent/metastatic head and neck squamous cell carcinoma, supporting a less frequent dosing regimen.

Bicara Therapeutics announced the selection of 1500 mg of ficerafusp alfa as the optimal Phase 3 dose for its FORTIFI-HN01 study and provided its 2026 corporate outlook, emphasizing accelerated enrollment and potential commercialization.

Bicara Therapeutics announced preliminary Phase 1b expansion cohort data for ficerafusp alfa plus pembrolizumab, showing high response rates and advancing pivotal study dose selection.

Bicara Therapeutics announced its third-quarter 2025 financial results and business updates, highlighted by FDA Breakthrough Therapy Designation for ficerafusp alfa in 1L HPV-negative R/M HNSCC.

Bicara Therapeutics announced its second quarter 2025 financial results, highlighting strong cash reserves and positive clinical trial data for ficerafusp alfa.

Bicara Therapeutics Inc. announced that its stockholders successfully elected three Class I directors and ratified KPMG LLP as the independent registered public accounting firm for 2025 at its recent annual meeting.

Bicara Therapeutics Inc. has entered into a sublease agreement for an additional 9,682 square feet of office space at its Boston headquarters, effective June 4, 2025, with a term ending June 30, 2027.

Bicara Therapeutics announced its first quarter 2025 financial results, highlighting progress in clinical trials and a strong cash position.

Bicara Therapeutics announces its Q4 and full year 2024 financial results, showcasing a strong cash position and advancements in its lead asset, ficerafusp alfa.

Bicara Therapeutics is progressing its lead candidate, ficerafusp alfa (FICERA), in clinical trials, particularly for recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC), with promising early results and a clear regulatory path.

Bicara Therapeutics reported strong financial results for the third quarter of 2024, highlighted by a successful IPO and progress in clinical trials for their lead drug candidate, ficerafusp alfa.

Bicara Therapeutics has updated its certificate of incorporation and bylaws to reflect changes related to its recent initial public offering.